Novocure
Zug, Zug, Switzerland · Biotechnology, Health Care, Medical
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure ha
Key facts
- Headquarters
- Zug, Zug, Switzerland
- Employees
- 1,467
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (NVCR)
- Website
- www.novocure.com
- Company page
Recent activity at Novocure
- : SEC 8-K (7.01):
- : NovoCure Limited Announces Retirement of Director Timothy Scannell
- : SEC 8-K (5.02): Timothy Scannell, a director of NovoCure Limited, has retired from the Board effective September 2, 2026, after five years of service. His retirement was not due to any disagreement with the Company or its management. This change in the Board's composition may have implications for the governance and strategic direction of the Company as it moves forward without Scannell's leadership.
- : SEC 8-K (8.01):
- : SEC 8-K (7.01): On June 30, 2026, NovoCure Limited announced via press release that Optune Pax® has received the CE Mark for treating adult patients with locally-advanced pancreatic cancer of exocrine origin, used in conjunction with gemcitabine and nab-paclitaxel. This approval aligns with guideline recommendations while accounting for market variations in treatments. The CE Mark signifies a crucial step in expanding the therapeutic options for patients, potentially impacting market presence in Europe significantly.
- : SEC 8-K (7.01): On June 18, 2026, NovoCure Limited issued a press release announcing the top line results from its Phase 3 TRIDENT trial evaluating Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM). The trial compared early initiation of TTFields therapy alongside chemoradiation against therapy initiated during the maintenance phase. The findings indicated no statistically significant improvement in overall survival, with median overall survival reported at 17.7 months for the Early Start Arm versus 17.5 months for the Maintenance Start Arm (p=0.519). The trial's results will be presented at the upcoming American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, and the results are important for understanding the therapeutic implications of TTFields in GBM treatment.
- : SEC 8-K (5.02): On June 3, 2026, NovoCure Limited held its annual general meeting of shareholders where shareholders elected eleven new directors: Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford, and William Vernon. These directors will serve until the annual meeting of shareholders in 2027. The election was not based on any arrangements between the nominees and third parties, and they will be compensated according to the existing non-employee director compensation programs. A total of 93,826,730 shares, or approximately 81.01% of the total shares eligible to vote, were represented at the meeting.
- : SEC 8-K (7.01): On June 30, 2026, NovoCure Limited announced via a press release that its product Optune Pax® has received a CE Mark, permitting its use for the treatment of adult patients with locally-advanced pancreatic cancer of exocrine origin. This treatment is intended to be used in conjunction with gemcitabine and nab-paclitaxel, in accordance with specific guideline recommendations. The CE Mark approval reflects the company's commitment to adapting its offerings to local market conditions, acknowledging that the use of these drugs may vary across different regions. This announcement could significantly enhance patient treatment options in Europe, thereby impacting the company's market position and growth prospects.
- : SEC 8-K (5.02): On April 8, 2026, NovoCure Limited announced an amendment to the compensation arrangement with Uri Weinberg, M.D., Ph.D., who has been appointed as Chief Medical Officer in addition to his existing role as Chief Innovation Officer. The modification, outlined in the Weinberg Letter Agreement dated April 7, 2026, includes a salary increase of CHF 5,000 per month for as long as he holds the Chief Medical Officer position. This change reflects the company's strategic commitment to enhancing its leadership in medical innovation and management. The agreement is documented in full in Exhibit 10.1 attached to the filing.
- : SEC 8-K (7.01): On March 26, 2026, NovoCure Limited issued a Regulation FD Disclosure announcing the positive results from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy in combination with atezolizumab (Tecentriq®), gemcitabine, and nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma. The trial met its primary endpoint, showing a significant improvement in disease control rate (DCR) of 74.4% compared to 48% in the historical control group, with a statistically significant difference of 26.4% and a p-value of < 0.001. This announcement highlights the potential impact of TTFields therapy on treatment outcomes for patients with mPDAC, adding significant insights to the ongoing research in this field.
Novocure funding history
| Date | Round | Amount |
|---|---|---|
| May 2024 | Debt Financing | $400.0M |
Leadership
- Timothy Scannell, Director
- Ethan Martin, Senior Oncology Territory Manager
- Galit Katz, Senior Talent Acquisition Partner
- Uri Weinberg, Chief Innovation Officer
- Frank Leonard, Chief Executive Officer
- Mukund Paravasthu, Chief Operating Officer
- Nicolas Leupin, Chief Medical Officer
Verified email and direct lines for Novocure’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Novocure in the news
- Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma - Business Wire (Jun 18, 2026)
- Novocure to Report Second Quarter 2026 Financial Results - Business Wire (Jul 01, 2026)
- U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer - Business Wire (Feb 11, 2026)
- Novocure’s Tumor Treating Fields: Innovative brain cancer therapy with survival and safety benefits - Nature (Sep 27, 2018)
- Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer - Business Wire (Jun 30, 2026)
- Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer - Business Wire (Oct 01, 2026)
- Novocure Reports First Quarter 2026 Financial Results - Business Wire (Apr 30, 2026)
- Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance - Business Wire (Oct 29, 2026)
Companies similar to Novocure
- ShockWave Medical · Biotechnology, Health Care, Medical, Therapeutics
- Alexion · Biotechnology, Health Care, Medical, Therapeutics
- Glaukos Corporation · Biotechnology, Health Care, Medical, Therapeutics
- Corcept · Biotechnology, Health Care, Medical, Therapeutics
- Vectura Group Limited · Biotechnology, Health Care, Medical, Therapeutics
About Novocure: questions and answers
What does Novocure do?
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure ha
Where is Novocure headquartered?
Novocure is headquartered in Zug, Zug, Switzerland.
How many employees does Novocure have?
Novocure has about 1,467 employees.
Has Novocure raised funding?
Yes. Fundz has recorded 1 funding event for Novocure. The most recent, Debt Financing of $400.0M, was in May 2024.
Who leads Novocure?
Frank Leonard is a Chief Executive Officer at Novocure.
What is the latest news on Novocure?
On Oct 01, 2026, SEC 8-K (7.01):
Is Novocure a public company?
Yes. Novocure is publicly traded under the ticker NVCR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy